Literature DB >> 21080606

Prevention: Neuropsychiatric adverse effects signal the end of the line for rimonabant.

Alexandra King.   

Abstract

Year:  2010        PMID： 21080606     DOI： 10.1038/nrcardio.2010.148

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  1 in total

1.  Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.

Authors:  Eric J Topol; Marie-Germaine Bousser; Keith A A Fox; Mark A Creager; Jean-Pierre Despres; J Donald Easton; Christian W Hamm; Gilles Montalescot; P Gabriel Steg; Thomas A Pearson; Eric Cohen; Christophe Gaudin; Bernard Job; Judith H Murphy; Deepak L Bhatt
Journal:  Lancet       Date:  2010-08-14       Impact factor: 79.321
  1 in total
  3 in total

Review 1.  Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework.

Authors:  David Cook; Dearg Brown; Robert Alexander; Ruth March; Paul Morgan; Gemma Satterthwaite; Menelas N Pangalos
Journal:  Nat Rev Drug Discov       Date:  2014-05-16       Impact factor: 84.694

2.  Convulsant doses of abused synthetic cannabinoid receptor agonists AB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA and JWH-018 do not elicit electroencephalographic (EEG) seizures in male mice.

Authors:  Catheryn D Wilson; Fang Zheng; William E Fantegrossi
Journal:  Psychopharmacology (Berl)       Date:  2022-08-06       Impact factor: 4.415

3.  Targeted inactivation of GPR26 leads to hyperphagia and adiposity by activating AMPK in the hypothalamus.

Authors:  Daohong Chen; Xiaolei Liu; Weiping Zhang; Yuguang Shi
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.